On December 1, 2011, the Federal Circuit declined to overturn a lower court ruling that Finnegan client AstraZeneca PLC did not infringe a Teva patent through its sales of the billion-dollar cholesterol drug Crestor®. The court held that Teva’s patent for a stabilized statin formulation of rosuvastatin calcium for the treatment of dyslipidemia was invalid since AstraZeneca was first to invent the pharmaceutical compound.
Commentary
NVLSP, Veterans Groups File Amicus Brief, Urge Supreme Court Review Federal Circuit’s Skaar Decision
April 4, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.